Taxane

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Retrieved on: 
Thursday, January 6, 2022
Perampanel, Therapy, Tumor hypoxia, HIV disease progression rates, Patient, Anthracycline, Adult, Eribulin, Intention, Cancer, GUD, Annual report, Breast cancer, TSX, Leiomyosarcoma, Phenotype, Gene, Liposarcoma, Woman, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), OS, GLOBE, Halichondrin B, Taxane, Nature, Pharmaceutical industry, Medical imaging, Knight, Uniting Medically Supervised Injecting Centre, Eisai

MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven (eribulin) injection.

Key Points: 
  • MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven (eribulin) injection.
  • Halaven (eribulin) injection has shown to significantly improve overall survival in patients with advanced or metastatic breast cancer after anthracycline and taxane treatment.
  • Were pleased to announce the approval of Halaven (eribulin) injection in Colombia as it provides a new treatment option for metastatic breast cancer and liposarcoma, said Samira Sakhia, President & Chief Executive Officer.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com .

G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

Retrieved on: 
Wednesday, December 1, 2021
Patient, Private Securities Litigation Reform Act, Lung, Day 1, Trial of the century, HER2, Safety, Risk, Trilaciclib, G1 Therapeutics, Forward-looking statement, Company, Progesterone, Bladder cancer, PARK, Toxicity, Immunohistochemistry, Cancer, Tumor microenvironment, Research Triangle Park, Carboplatin, Breast, Neoplasm, American Cancer Society, Taxane, Breast cancer, RESEARCH, Biopsy, Chain reaction, Nasdaq, GLOBE, TILS, RNA transfection, Regulatory T cell, U.S. Securities and Exchange Commission, Radiation, Therapy, TNBC, Medical imaging, Pharmaceutical industry

Those preliminary data support the important role trilaciclib may play in treating cancer by enhancing T cell activation and favorably altering the tumor microenvironment.

Key Points: 
  • Those preliminary data support the important role trilaciclib may play in treating cancer by enhancing T cell activation and favorably altering the tumor microenvironment.
  • Approximately 30 patients will be enrolled in this Phase 2 multicenter, open-label, single-arm, neoadjuvant study.
  • Patients will receive a single dose of monotherapy trilaciclib, followed by a tumor biopsy approximately one week later.
  • G1 Therapeutics and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

LIPAC Oncology to Present Two-year Data for Phase 1/2a Study of LiPax at the 22nd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Monday, November 15, 2021
Safety, Bladder cancer, EORTC, Nano, Recurrence, Mesothelioma, Society, NMIBC, UTUC, Company, Toxicity, Cancer, Patient, Taxane, Malignant pleural effusion, Medical imaging, Pharmaceutical industry

ET

Key Points: 
  • ET
    LiPax is a precision targeted, locally delivered taxane in Phase 2b development for intravesical instillation in the treatment of non-muscle invasive bladder cancer (NMIBC).
  • LIPAC Oncology completed a Phase 2a clinical trial in August 2020 and intends to initiate a Phase 2b study in the second half of 2021 to further investigate LiPax in the treatment of this condition.
  • LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers.
  • LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development.

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, NASDAQ, Cancer, Wind, Therapy, Patient, Odonata, Taxane, Pharmaceutical industry

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021.

Key Points: 
  • Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021.
  • As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020.
  • Odonates cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively.
  • In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations.

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

Retrieved on: 
Monday, October 18, 2021
CTC, Phenotype, Cancer, Private Securities Litigation Reform Act, Agitation, Pembrolizumab, Nasdaq, Achievement, ESMO, Lists of diseases, Senior, Observation, MCRPC, Man, RECIST, Algorithm, Tumor microenvironment, Dexmedetomidine, Population, De novo, Adenocarcinoma, SEC, BID, Artificial intelligence, Inflammation, Patient, Progression-free survival, GLOBE, Trial of the century, SCNC, Company, Forward-looking statement, Drug development, Psychiatry, Safety, Prostate cancer, Patent, Taxane, Therapy, Drug discovery, COVID-19, Pharmaceutical industry

NEW HAVEN, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop potentially transformative medicines in neuroscience and immuno-oncology, today announced that it has expanded its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, orally administered innate immune activator, in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients with either de novo or treatment-emergent small-cell neuroendocrine carcinoma (SCNC). The Company’s decision to advance BXCL701 into the second stage of the Phase 2a efficacy portion of the study follows the achievement of the protocol-specified efficacy threshold for cohort expansion, meaning observation of three composite responses.

Key Points: 
  • The Phase 1b/2 trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 in combination with pembrolizumab for men with mCRPC presenting with either SCNC or adenocarcinoma phenotypes.
  • As of October 18, three of ten SCNC evaluable patients achieved composite response, satisfying the protocol-specified threshold for continued expansion.
  • BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment.
  • BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

Retrieved on: 
Thursday, October 7, 2021
Twitter, Part Two, IHC, Neoplasm, Patient, Pharmacokinetics, EGFR, ID, Risk, Ovarian cancer, Part, Lapatinib, COVID-19, Prostate cancer, AR, NSCLC, LinkedIn, Safety, Industry, Webcast, Population, SEC, Securities Exchange Act of 1934, FDA, MD, EED, U.S. Securities and Exchange Commission, CD73, Securities Act of 1933, Security (finance), ORIC, Plasma, Gene expression, Drug Quality and Security Act, Key finding attacks, Tucatinib, Therapy, PRC2, Taxane, Biomarker, GR, HER2, Medical imaging, Pharmaceutical industry, Vaccine

Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.

Key Points: 
  • Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.
  • Enrollment continues in the Part II dose expansion cohorts at nine clinical sites across the United States.
  • Based on preclinical and clinical studies, ORIC-101 is expected to have reduced drug-drug interaction liabilities than other glucocorticoid receptor antagonists.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

LIPAC Oncology Secures Broad Patent Protection for Proliposomal Paclitaxel Compositions Formulated for Delivery to the Bladder and Ureter for the Treatment of Solid Tumor Carcinomas

Retrieved on: 
Thursday, October 7, 2021
Company, Patent, Union, Paclitaxel, European Union, IP, UTUC, Robbert Vos, Cancer, Toxicity, Bladder cancer, Nano, Clear-cell ovarian carcinoma, Malignant pleural effusion, Mesothelioma, NMIBC, Taxane, Pharmaceutical industry, Medical imaging

LIPAC also has multiple pending patent applications directed to related treatment methods of bladder and ureter solid tumor carcinomas, as well methods of treating intraperitoneal tumors, including ovarian carcinomas.

Key Points: 
  • LIPAC also has multiple pending patent applications directed to related treatment methods of bladder and ureter solid tumor carcinomas, as well methods of treating intraperitoneal tumors, including ovarian carcinomas.
  • LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers.
  • Its precision liposome-bound nano-technology platform targets local liposomal delivery of taxanes for the treatment of multiple tumor types.
  • LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development.

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

Retrieved on: 
Wednesday, September 15, 2021
Trial of the century, Hypotension, Cancer, Artificial intelligence, Therapy, Man, MCRPC, Drug discovery, NEW, PSA, Drug development, Forward-looking statement, Prostate cancer, AES, Taxane, Inflammation, Patient, ESMO, Company, Pembrolizumab, Private Securities Litigation Reform Act, Patent, Nasdaq, Algorithm, Agitation, Fatigue, European Society for Medical Oncology, Neoplasm, Safety, Adenocarcinoma, BID, SCNC, COVID-19, Progression-free survival, Tumor microenvironment, Senior, Lists of diseases, Psychiatry, Itch, PD-1, GLOBE, Dexmedetomidine, Rash, SEC, Oncology, Congress, Medical imaging, Pharmaceutical industry

NEW HAVEN, Conn., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced data from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate carcinoma (mCRPC) in a poster presentation at the 2021 European Society for Medical Oncology (ESMO) Congress.

Key Points: 
  • Further, the majority of these responders who received BXCL701 in combination with pembrolizumab did not have strong predictive markers of pembrolizumab response.
  • The Phase 1b/2 trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 in combination with pembrolizumab, in men with mCRPC adenocarcinoma and SCNC phenotypes.
  • The primary endpoint of the trial is composite response rate, with a target of achieving >15% response.
  • BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Retrieved on: 
Thursday, May 13, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Chemotherapy, Oncology, Chemotherapy-induced peripheral neuropathy, Taxane, Breast cancer, Causes of cancer pain, OSM-0205 and CIPN, Osmol Therapeutics, OSM-0205 AND CIPN, OSMOL THERAPEUTICS

b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Key Points: 
  • b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).
  • OSM-0205\xe2\x80\x99s mechanism addresses the off-target toxicity of microtubule-based chemotherapy agents that results in a calcium surge leading to CIPN.
  • Taxanes are the most widely used chemotherapy treatment for breast cancer and can lead to CIPN in up to 80% of patients.
  • The company\xe2\x80\x99s lead indication will be for the prevention of CIPN in breast cancer patients treated with taxane-based therapy, a treatment regimen in which up to 80% of patients experience CIPN.

Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal

Retrieved on: 
Monday, November 18, 2019
Organic compounds, Cancer, RTT, Clinical medicine, Carbamates, Taxanes, Taxane, Cabazitaxel, Docetaxel, Prostate cancer, Chemotherapy, FABP5

(Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et.

Key Points: 
  • (Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth, Carbonetti et.
  • Taxanes, such as docetaxel and cabazitaxel are utilized in standard treatment regimens for chemotherapy nave castrationresistant prostate cancers.
  • FABP5 is an intra-cellular protein chaperone that serves as a carrier for fatty acids that trigger increased expression of genes associated with tumor angiogenesis and reduced patient survival.
  • Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.